Jideytro (zidesamtinib)
Nuvalent (NUVL)
ApprovedJul 22, 2026
Marketer take
For ROS1-positive lung cancer after a prior ROS1 inhibitor, a small biomarker-defined group, so thoracic oncologists and testing labs are the audience and competing ROS1 brands should expect sequencing messages.
- Sponsor company
- Nuvalent (NUVL)
- Indication
- To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor
- Therapeutic area
- Oncology
- Event
- FDA approval
- Date
- Jul 22, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?